IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

AGHEMO, ALESSIO MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.512
NA - Nord America 6.921
AS - Asia 5.572
SA - Sud America 715
AF - Africa 180
OC - Oceania 50
Continente sconosciuto - Info sul continente non disponibili 15
Totale 23.965
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.587
GB - Regno Unito 4.055
DE - Germania 2.420
CN - Cina 2.009
SG - Singapore 1.552
IT - Italia 984
SE - Svezia 860
RU - Federazione Russa 573
BR - Brasile 540
HK - Hong Kong 493
IN - India 403
TR - Turchia 311
CA - Canada 259
FR - Francia 254
IE - Irlanda 239
UA - Ucraina 233
NL - Olanda 215
KR - Corea 174
FI - Finlandia 171
VN - Vietnam 127
EU - Europa 114
ID - Indonesia 103
DK - Danimarca 102
JP - Giappone 78
CO - Colombia 68
ES - Italia 60
CI - Costa d'Avorio 57
PL - Polonia 57
BE - Belgio 54
MX - Messico 48
GR - Grecia 43
AU - Australia 40
CH - Svizzera 40
AR - Argentina 37
TW - Taiwan 33
BD - Bangladesh 32
RO - Romania 32
EG - Egitto 29
IR - Iran 29
AT - Austria 27
UZ - Uzbekistan 25
TH - Thailandia 24
IQ - Iraq 23
EC - Ecuador 21
KH - Cambogia 20
PK - Pakistan 20
ZA - Sudafrica 20
IL - Israele 19
MA - Marocco 18
PT - Portogallo 15
CL - Cile 14
AE - Emirati Arabi Uniti 13
JO - Giordania 12
PE - Perù 12
LT - Lituania 11
HU - Ungheria 10
NO - Norvegia 10
SA - Arabia Saudita 10
VE - Venezuela 10
ET - Etiopia 9
TN - Tunisia 9
UG - Uganda 9
KZ - Kazakistan 8
PH - Filippine 8
CZ - Repubblica Ceca 7
MY - Malesia 6
NZ - Nuova Zelanda 6
PS - Palestinian Territory 6
UY - Uruguay 6
AZ - Azerbaigian 5
LV - Lettonia 5
MK - Macedonia 5
NG - Nigeria 5
OM - Oman 5
RS - Serbia 5
BO - Bolivia 4
DZ - Algeria 4
EE - Estonia 4
KE - Kenya 4
KG - Kirghizistan 4
NP - Nepal 4
PA - Panama 4
AL - Albania 3
BB - Barbados 3
BG - Bulgaria 3
CR - Costa Rica 3
LB - Libano 3
LK - Sri Lanka 3
MD - Moldavia 3
PY - Paraguay 3
SK - Slovacchia (Repubblica Slovacca) 3
WS - Samoa 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CU - Cuba 2
DO - Repubblica Dominicana 2
GH - Ghana 2
GT - Guatemala 2
Totale 24.027
Salva come PNG Salva come JPEG
Città #
Southend 3.730
Singapore 836
Ashburn 712
Chandler 670
Hong Kong 443
Frankfurt am Main 433
Beijing 405
Seattle 393
Milan 377
Dallas 326
Princeton 283
Hanover 274
Wilmington 263
Fairfield 238
Dublin 232
Ann Arbor 212
Toronto 166
Woodbridge 163
Dearborn 159
Jacksonville 157
Council Bluffs 155
Los Angeles 139
Nanjing 137
Bengaluru 122
Houston 117
Santa Clara 117
Mountain View 114
Redmond 95
Des Moines 94
Guangzhou 94
Buffalo 92
Boardman 91
Cambridge 87
Andover 83
Redwood City 82
New York 77
Munich 76
Shanghai 68
Berlin 64
Jinan 63
Phoenix 63
Sakarya 61
Columbus 60
Hefei 60
Serra 60
Jakarta 59
Abidjan 57
Istanbul 55
Moscow 55
Somerville 53
Bogotá 50
Ottawa 48
São Paulo 48
Cangzhou 46
Shenyang 46
The Dalles 45
Brussels 44
Helsinki 43
Saint Petersburg 43
Nanchang 42
Tianjin 40
Tokyo 40
Grafing 39
Changsha 36
Hanoi 35
San Diego 32
Mumbai 31
Warsaw 31
Zhengzhou 31
Athens 30
Ho Chi Minh City 30
London 30
Eitensheim 28
Jiaxing 28
Hebei 25
Chengdu 23
Fuzhou 23
Wuhan 23
Brooklyn 20
Hangzhou 20
Phnom Penh 20
Taipei 20
Belo Horizonte 19
Nuremberg 19
Ankara 18
Rome 18
Central District 17
Kent 17
Pune 17
Auburn Hills 16
Dong Ket 16
Düsseldorf 16
Kunming 16
Seoul 16
Shenzhen 16
Silver Spring 16
Turku 16
Fremont 15
Margão 15
Turin 15
Totale 14.410
Salva come PNG Salva come JPEG
Nome #
COVID-19 and liver disease 843
Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection 669
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 527
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 398
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients 347
Prevalence of psychiatric disorders during PEG – Interferon and Ribavirin therapy in patients with chronic hepatitis HCV-correlated 344
Real life experiences in HCV management in 2018 344
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 322
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 300
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease 293
Indolent B-cell lymphomas treated upfront with antiviral therapy : a series of 13 patients 269
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 259
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 253
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 252
High rates of 30-day mortality in patients with cirrhosis and COVID-19 248
Donor/recipient match of IL28B to predict interferon response in recurrent hepatitis C 246
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 235
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegykated interferon-α2A in chronic hepatitis C : an in vitro and in vivo study 228
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 224
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir 222
Liver stiffness measurement reliability and main determinants of point shear-wave elastography in patients with chronic liver disease 218
Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients 217
US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C 212
Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method 211
S1pr2 is a key mediator of endoplasmic reticulum stress in NAFLD/ NASH pathogenesis 211
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 208
Genotype dependent pattern of peginterferon alfa-2b/ribavirin treatment failure in hepatiti sC virus infected patients with cirrhosis : a single center study of 471 naive patients 207
Recovery after L-DOPA treatment in peg-interferon and ribavirin induced parkinsonism 206
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C 203
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 203
New horizons in hepatitis C antiviral therapy with direct-acting antivirals 202
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 201
High levels of factor VIII and risk of extra-hepatic portal vein obstruction 200
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 198
Allelic inhibition of displacement activity : a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 198
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C 195
Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients 195
Hepatitis C virus genotypes and patterns of peginterferon alfa-2b/ribavirin treatment failure in patients with cirrhosis : a single center study of 471 naïve patients 193
In vivo and in vitro effect of ribavirin and interferon on erythropoiesis in patients with hepatitis C 193
The influence of liver fibrosis on the outcome of pegylated interferon and ribavirin anti-hac therapy : a sub-analysis of the mist study 191
Genotype dependent pattern of Peginterferon alfa-2B/Ribavirin treatment failure in hepatitis C virus infected patients with cirrhosis : a single centre study of 471 naïve patients 191
Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis 191
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy 190
The natural history of portal hypertension in patients with HCV related compensated cirrhosis undergoing interferon ribavirin therapy 188
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? 187
The diagnostic accuracy of fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with an SVR 185
A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients 184
Increased survival of patients with HCV-related cirrhosis with a long-term response to interferon therapy 182
NPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C 181
Effect of the PNPLA3 I148M polymorphism on the outcome of peg-interferon plus ribavirin treatment in chronic hepatitis C 181
Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives 181
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 181
Individualized hepatocellular carcinoma risk : the challenges for designing successful chemoprevention strategies 180
PNPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C 177
Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients : a single-centre study 175
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 175
Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis 174
Daclatasvir : a team player rather than a prima donna in the treatment of hepatitis C 174
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients 174
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 174
Increased risk of hepatocellular carcinoma in HCV (+) non responder cirrhotics with high liver cell proliferation 171
Deciding on interferon-free treatment for chronic hepatitis C : Updating liver stiffness cut-off values to maximize benefit 170
Interferoni pegilati nel trattamento dei pazienti con epatite cronica HCV : esperienze a confronti 169
Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection 169
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 168
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 167
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 166
Anti-TNF drugs in patients with hepatitis B or C virus infection : safety and clinical management 163
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 162
Evaluation of liver disease in a cohort of patients affected by thalassemia intermedia 161
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 161
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 161
Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3α hepatitis C virus infection 160
In vivo and in vitro effect of ribavirin and pegylated-interferon on erythropoiesis in patients with hepatitis C 160
Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis 159
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-α2a in chronic hepatitis C: an in vitro and in vivo study 159
The natural history of hepatic macroregenerative nodules developing in cirrhotic patients during surveillance with ultrasound (US) 157
Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis 157
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 157
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients 156
Low rates of sustained virological response to interferon and ribavirin therapy in genotype 3 infected patients with compensated cirrhosis 155
Hepatorenal syndrome and novel advances in its management 153
Renal safety in 3264 HCV patients treated with DAA-based regimens : results from a large Italian real-life study 153
Meccanismi patogenetici dell'anemia in corso di terapia antivirale in pazienti con epatite cronica HCV correlata 151
The natural history of macroregenerative nodules prospectively detected in cirrhotic patients under surveillance 151
Lack of alanine aminotransferase normalization in patients with an anti-hcv virological response during pegylated interferon and ribavirin therapy : a sub-analysis of the mist study 150
Prospective study of dysplastic nodules in cirrhosis : correlation with CT vascular pattern, histology and development of hepatocellular carcinoma 149
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 149
Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C 149
Liver cell proliferation and liver cancer risk in patients with hepatitis C virus-related cirrhosis under antiviral treatment 146
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 146
Prospective study of dysplastic nodes in cirrhotic patients : correlation with CT vascular pattern 145
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection : a predictor of spontaneous viral clearance and sustained virological response 145
New kids on the blocks for anti-HCV therapy 143
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 143
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure 142
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study 141
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 139
Treatment of chronic hepatitis C with pegylated interferon-α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura 138
Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics? 137
Totale 20.688
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.711
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.711
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.866 0 0 0 0 0 209 209 255 337 183 476 197
2021/20222.456 204 134 116 152 208 207 219 210 243 286 134 343
2022/20232.287 286 286 197 281 232 423 66 106 232 41 101 36
2023/20241.572 50 131 91 111 375 115 109 112 40 87 159 192
2024/20253.554 165 356 76 428 287 135 125 321 213 365 346 737
2025/20263.320 780 409 824 552 724 31 0 0 0 0 0 0
Totale 25.146